Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F3 | P13726 | 3/20 | 0.85 |
| ▸ | MAPT | P10636 | 5/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.77 |
| ▸ | RAB9A | P51151 | 4/20 | 0.77 |
| ▸ | MAOB | P27338 | 3/20 | 0.77 |
| ▸ | MEN1 | O00255 | 3/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.77 |
| ▸ | HSPD1 | P10809 | 2/20 | 0.77 |
| ▸ | HSPE1 | P61604 | 2/20 | 0.77 |
| ▸ | MAOA | P21397 | 2/20 | 0.77 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.77 |
| ▸ | PKM | P14618 | 1/20 | 0.77 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.77 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.77 |
| ▸ | RELA | Q04206 | 1/20 | 0.77 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.77 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.77 |
| ▸ | ESR1 | P03372 | 1/20 | 0.72 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9100389 | 1.00 | F3 (0.85) | F3MAPTKMT2ARAB9AMAOB | |
| SCHEMBL10299734 | 1.00 | F3 (0.85) | F3MAPTKMT2ARAB9AMAOB | |
| SCHEMBL25208810 | 1.00 | F3 (0.85) | F3MAPTKMT2ARAB9AMAOB | |
| SCHEMBL25216179 | 1.00 | F3 (0.85) | F3MAPTKMT2ARAB9AMAOB | |
| SCHEMBL25195971 | 0.92 | XDH (0.74) | F3MAPTKMT2ARAB9AMAOB | |
| 4,4'-Dihydroxychalcone SCHEMBL25202156 | 0.92 | F3 (1.00) | F3MAPTKMT2ARAB9AMAOB | |
| SCHEMBL25223420 | 0.92 | F3 (1.00) | F3MAPTKMT2ARAB9AMAOB | |
| SCHEMBL25201250 | 0.92 | XDH (0.74) | F3MAPTKMT2ARAB9AMAOB | |
| SCHEMBL25211913 | 0.92 | F3 (1.00) | F3MAPTKMT2ARAB9AMAOB | |
| SCHEMBL25236411 | 0.92 | F3 (1.00) | F3MAPTKMT2ARAB9AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2024233598-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-4429763-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | Yewsavin, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023086388-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
| EP-0712388-A1 | USE OF PHENOLS AND PHENOL DERIVATES AS MEDICAMENTS WITH FIBRINOGEN-REDUCING EFFECT | Roche Diagnostics GmbH (DE) | 1996-05-22 | — | — | EP | disclosed |
| WO-1995005358-A1 | USE OF PHENOLS AND PHENOL DERIVATES AS MEDICAMENTS WITH FIBRINOGEN-REDUCING EFFECT | BOEHRINGER MANNHEIM GMBH (DE) | 1995-02-23 | — | — | WO | disclosed |
| US-4190671-A | ANTIINFLAMMATORY, ANTIALLERGENIC, ANTIULCER | BIOREX LABORATORIES LIMITED (GB) | 1980-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | F3 5/4885MAPT 3297/4885KMT2A 2792/4885 |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | SERPINC1, SERPINE1, SERPINH1 | F3 11/4885MAPT 3512/4885KMT2A 3188/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | F3 11/4885MAPT 3512/4885KMT2A 3188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.